Swiss Re transfered $75 million of U.S. and U.K. extreme mortality risk to the capital markets through a new securitization program called VITA Capital IV Ltd.

The transaction covers a five-year risk period starting in the issuance year and ending in 2014.  The notes are rated 'BB+' by Standard & Poor’s.

Subscribe Now

Access to a full range of industry content, analysis and expert commentary.

30-Day Free Trial

No credit card required. Access coverage of the securitization marketplace, including breaking news updated throughout the day.